Enhancement of Gemifloxacin Solubility and Bioavailability Using Hydroxypropyl-β-Cyclodextrin: In Vitro and In Vivo Evaluation
International Journal of Pharmacology · 01.06.2026 · 22 (3)
DOI: 10.31083/ijp50190 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Pharmacology, online erschienen am 01.06.2026. Verfasst von Jong Woo Kim und 4 weiteren Autor:innen. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Korea Health Technology R&D Project through the Korea Health Industry Development Institute, Ministry of Health & Welfare, Republic of Korea.
Abstract (Originalsprache)
Background and Objective: Various solubilizing agents were used to improve the solubility of gemifloxacin, which has limited water solubility. Furthermore, the solubility enhancement and bioavailability of gemifloxacin were then assessed through in vitro solubility screening and in vivo pharmacokinetic studies in rats. Materials and Methods: Different solubilizing agents, including poloxamer 407, poloxamer 188, Soluplus®, Polyox N80, sodium lauryl sulfate, PEG 4000, L-arginine, L-lysine, β-cyclodextrin, and hydroxypropyl-β-cyclodextrin (HPCD), were evaluated for the associated solubilizing effects, and HPCD was selected as the optimal solubilizer. Gemifloxacin in samples collected from the in vitro and in vivo experiments was quantified using high-performance liquid chromatography (HPLC).
Results
In vitro solubility screening showed that the solubility of gemifloxacin reached 69.37 ± 0.71 mg/mL with 4.1 g of HPCD, representing a 1.52-fold increase relative to the control group (45.68 ± 0.37 mg/mL). Further optimization revealed that 0.1 g of HPCD achieved a solubility of 66.27 ± 0.42 mg/mL, with minimal additional improvement at higher concentrations. The HPLC method exhibited excellent linearity (R2 = 0.9998) over the range of 0.03–45 μg/mL. The in vivo pharmacokinetic study demonstrated that the area under the curve (AUC0-∞) of the gemifloxacin–HPCD formulation (Group A: 7.527 ± 0.60 μg⋅h/mL) increased approximately 1.53-fold compared with that of the gemifloxacin-alone group (4.928 ± 0.85 μg⋅h/mL), significantly improving the bioavailability of gemifloxacin.
Conclusion
The solubilization strategy using HPCD can effectively improve the solubility and bioavailability of gemifloxacin, representing a promising approach for the development of the associated oral formulations.
Förderung
- Korea Health Technology R&D Project through the Korea Health Industry Development Institute
- Ministry of Health & Welfare, Republic of Korea
Zitieren
APA
Kim, J. W., Kang, J. S., Park, G. E., Kim, Y. H., & Kim, K. M. (2026). Enhancement of Gemifloxacin Solubility and Bioavailability Using Hydroxypropyl-β-Cyclodextrin: In Vitro and In Vivo Evaluation. International Journal of Pharmacology, 22(3). https://doi.org/10.31083/ijp50190
Vancouver
Kim JW, Kang JS, Park GE, Kim YH, Kim KM. Enhancement of Gemifloxacin Solubility and Bioavailability Using Hydroxypropyl-β-Cyclodextrin: In Vitro and In Vivo Evaluation. International Journal of Pharmacology. 2026;22(3). doi:10.31083/ijp50190
BibTeX
@article{Kim2026,
author = {Kim, Jong Woo and Kang, Jae Seon and Park, Ga Eun and Kim, Yeon Hee and Kim, Kang Min},
title = {Enhancement of Gemifloxacin Solubility and Bioavailability Using Hydroxypropyl-β-Cyclodextrin: In Vitro and In Vivo Evaluation},
journal = {International Journal of Pharmacology},
year = {2026},
volume = {22},
number = {3},
doi = {10.31083/ijp50190}
}
EUVIMED